scispace - formally typeset
B

Brecht Guillemyn

Researcher at Ghent University Hospital

Publications -  16
Citations -  271

Brecht Guillemyn is an academic researcher from Ghent University Hospital. The author has contributed to research in topics: Osteogenesis imperfecta & Compound heterozygosity. The author has an hindex of 6, co-authored 15 publications receiving 184 citations.

Papers
More filters
Journal ArticleDOI

Mutations in ATP6V1E1 or ATP6V1A Cause Autosomal-Recessive Cutis Laxa

TL;DR: These findings expand the clinical and molecular spectrum of metabolic cutis laxa syndromes and further link defective extracellular matrix assembly to faulty protein processing and cellular trafficking caused by genetic defects in the V-ATPase complex.
Journal ArticleDOI

Defective Proteolytic Processing of Fibrillar Procollagens and Prodecorin Due to Biallelic BMP1 Mutations Results in a Severe, Progressive Form of Osteogenesis Imperfecta.

TL;DR: It is shown that BMP1/mTLD‐deficiency in humans not only results in delayed cleavage of the type I procollagen C‐propeptide but also hampers the processing of the small leucine‐rich proteoglycan prodecorin, a regulator of collagen fibrillogenesis.
Journal ArticleDOI

Genetic Defects in TAPT1 Disrupt Ciliogenesis and Cause a Complex Lethal Osteochondrodysplasia

TL;DR: It is demonstrated that TAPT1 mutations underlie a complex congenital syndrome, showing clinical overlap between lethal skeletal dysplasias and ciliopathies, and Knockdown of tapt1b in zebrafish induces severe craniofacial cartilage malformations and delayed ossification, which is shown to be associated with aberrant differentiation of cranial neural crest cells.
Journal ArticleDOI

A homozygous pathogenic missense variant broadens the phenotypic and mutational spectrum of CREB3L1-related osteogenesis imperfecta

TL;DR: The first homozygous pathogenic missense variant is identified in a patient with lethal OI, which is located within the highly conserved basic leucine zipper domain, four amino acids upstream of the DNA binding domain, and affects a critical residue in this functional domain, thereby decreasing the type I collagen transcriptional binding ability.